Nick Roberts Acquires 90 Shares of Diaceutics (LON:DXRX) Stock

Key Points

• Nick Roberts purchased 90 shares of Diaceutics on April 30 at GBX 167 (total £150.30) and previously bought 100 shares on March 2 at GBX 150.
• Shares opened at GBX 165.40, with 50/200-day moving averages around GBX 154, a market cap of ~£140M, a negative P/E of -91.89, and a 52‑week range of GBX 112.25–177.
• Shore Capital Group raised its price target from GBX 180 to GBX 215; analysts give Diaceutics a consensus "Buy" rating with an average target of GBX 193.33.

Diaceutics PLC (LON:DXRX - Get Free Report) insider Nick Roberts purchased 90 shares of the business's stock in a transaction that occurred on Thursday, April 30th. The stock was bought at an average cost of GBX 167 per share, for a total transaction of £150.30.

Nick Roberts also recently made the following trade(s):

• On Monday, March 2nd, Nick Roberts purchased 100 shares of Diaceutics stock. The stock was bought at an average cost of GBX 150 per share, for a total transaction of £150.

Diaceutics Price Performance

Shares of LON:DXRX opened at GBX 165.40 on Tuesday. The company's 50-day moving average is GBX 154.44 and its 200 day moving average is GBX 153.63. The company has a debt-to-equity ratio of 3.05, a quick ratio of 9.92 and a current ratio of 3.96. The company has a market capitalization of £139.98 million, a P/E ratio of -91.89 and a beta of 0.94. Diaceutics PLC has a fifty-two week low of GBX 112.25 and a fifty-two week high of GBX 177.

Wall Street Analyst Weigh In

Separately, Shore Capital Group boosted their price target on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Diaceutics has an average rating of "Buy" and an average price target of GBX 193.33.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.